Aethlon Medical (Nasdaq: AEMD) saw its shares surge more than 471% in premarket trading on Thursday, September 17, 2026, after the company announced a definitive all-stock merger agreement with privately held biotechnology company North Immunology. The transaction will take the private biotech public through a combination with the Nasdaq-listed company rather than a traditional initial public offering.

Deal Structure and Ownership

The transaction will combine the two companies through wholly owned subsidiaries Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC. The resulting company will be named North Immunology, Inc. and will list on the Nasdaq Capital Market under the new ticker symbol NRTX.

Under the terms of the agreement, North Immunology shareholders and new private investment in public equity (PIPE) investors will own approximately 95.25% of the combined company. Aethlon's existing shareholders will hold roughly 4.75% of the new entity, along with contingent value rights tied to the monetization of Aethlon's legacy Hemopurifier blood-filtration business. Contingent value rights are instruments that can provide holders with additional payments if specified milestones, such as a future asset sale, are achieved. Taken together with the planned name change and the handover to North Immunology's management, the ownership split means the listing will effectively center on the private biotech's clinical pipeline, while any payment tied to Aethlon's legacy Hemopurifier business depends on those milestones being achieved.

Oversubscribed $180 Million Private Placement

The merger announcement came alongside an oversubscribed $180 million private placement — meaning investor demand exceeded the capital ultimately raised — which was described as a sign that institutional appetite for the deal was strong.

The financing was led by a group of healthcare-focused investors including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, Sirenia Capital Management LP, Farallon Capital Management, Adage Capital Partners LP, and TCGX.

The $180 million figure includes the conversion of approximately $34 million in North Immunology's outstanding convertible promissory notes, together with any accrued interest, premiums, and fees. The proceeds are expected to fully fund the combined company's operations into the second half of 2028 — a runway that extends into the same year the company expects topline data from its planned Phase 1b and Phase 2b studies.

Lead Drug Candidate: NOR-101

North Immunology is focused on bispecific antibodies — engineered proteins designed to bind two distinct molecular targets — that address inflammatory pathways involved in immune-mediated diseases. Its lead candidate, NOR-101, is a half-life extended IL-13 x IL-18 bispecific antibody being developed primarily for atopic dermatitis, a chronic inflammatory skin condition also known as eczema. Half-life extension is a design technique meant to keep a drug active in the body for longer, which can allow less frequent dosing.

Clinical Timeline

The Phase 1a study of NOR-101 is expected to begin in the first quarter of 2027, with interim pharmacokinetic and safety data expected by mid-2027. Phase 1a trials are typically the first tests of an experimental drug in humans, focusing on safety and how the body processes it. The company plans to initiate both Phase 1b and Phase 2b studies for atopic dermatitis in 2027, with topline data from both trials expected in 2028.

Closing Conditions and Leadership

The merger is expected to close in the first quarter of 2027, pending shareholder, regulatory, and Nasdaq listing approvals. Once the transaction closes, North Immunology's existing management team and board of directors will lead the combined company. Those approvals are the gating items for closing timeline, and the same quarter is also when the NOR-101 Phase 1a study is expected to begin — making the opening months of 2027 the window in which both the corporate transition and the clinical program are slated to reach their first checkpoints.

According to TipRanks data, the most recent analyst rating on AEMD stock is a Hold, with a price target of $1.50.

Source: CoinCentral